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Abstract
An improved number of anti-fungal drugs are currently available for the treatment of invasive aspergillosis (IA). While serial
galactomannan index (GMI) measurement can be used to monitor response to treatment, the extent to which different anti-
fungal regimens can affect galactomannan levels is unknown. In 147 IA patients receiving either voriconazole (VCZ) or
conventional amphotericin B (CAB) in a multicentre clinical trial, we performed post-hoc analyses of GMI trends in relation to
outcomes. The generalized estimation equations approach was used to estimate changes in the effect size for GMI over
time within patients. Patients who received VCZ primary therapy and had good treatment response 12 weeks later showed
earlier decreases in GMI values at Week 1 and Week 2 (p = 0.001 and 0.046 respectively) as compared to patients who only
received CAB. At end-of-randomized therapy (EORT), which was a pre-set secondary assessment point for all patients who
switched from randomized primary (CAB or VCZ) to an alternative anti-fungal drug, treatment failure was associated with
increasing GMI at Weeks 1 and 2 in CAB-primary treated patients (p = 0.022 and 0.046 respectively). These distinct trends
highlight the variations in GMI kinetics with the use of different anti-fungal drugs and their implications in relation to IA
treatment response.
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Introduction
Invasive aspergillosis (IA) is the most common opportunistic
mold infection in immunocompromised patients and leads to
significant morbidity and mortality. The presence of neutropenia
and the concurrent use immunomodulatory agents not only hinder
the ability of the host to mount an efficient inflammatory response
against the pathogen but also make the monitoring of response to
anti-fungal treatment difficult. Galactomannan is a distinct
polysaccharide component of the Aspergillus cell wall and its
quantification can serve as a surrogate marker for fungal burden
[1]. The detection of galactomannan with the Platelia Aspergillus
EIA, the galactomannan index (GMI) has been adopted as a
criterion in the diagnosis of IA [2,3] and it has also been suggested
that serial determination of serum GMI may be useful for
monitoring the response to treatment [4]. Recently, we explored
the prognostic usefulness of serial GMI measurements and
reported that early GMI trends at Week 1 and Week 2 of anti-
fungal treatment were of value for predicting eventual clinical
outcomes [5]. Our analysis was based on the well-characterized IA
patient cohort in the landmark multicenter Global Aspergillosis
Study, which compared the efficacy of voriconazole (VCZ) versus
conventional amphotericin B deoxycholate (CAB) as primary
therapy for IA [6]. However the influence of the respective anti-
fungal agents on GMI trends was not delineated in the above
study.
Voriconazole has since become the recommended primary drug
of choice for treatment of IA [7]. However, alternative anti-fungal
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regimens, including amphotericin-based formulations and the
echinocandins, continue to be prescribed for IA patients when
voriconazole use is contraindicated due to intolerance, or in the
setting of azole-resistant Aspergillus species [8]. Furthermore, in
those regions where healthcare resources remain restricted,
amphotericin B deoxycholate continues to be a commonly used
anti-fungal agent [9]. The respective therapies may exhibit
differing efficacies and may also differentially influence GMI
measurements. This could have a critical bearing on the
interpretation of serial GMI trends in relation to clinical response.
However in this context, the effect of anti-fungal regimens on GMI
trends during treatment has never been studied.
Our hypothesis was that anti-fungal drugs could have distinct
influences on early GMI trends that may subsequently predict
clinical outcome. We tested this hypothesis, post-hoc, in a well-
characterized cohort of study patients who received either VCZ or
CAB for the primary treatment of IA.
Patients and Methods
The patients studied were from Protocol 150–307 of the Global
Comparative Aspergillosis Study, a multicenter randomized trial
conducted in Europe, Australia and Israel that compared the
efficacy of VCZ versus CAB for the primary treatment of IA. The
lead organiser of the study was the European Organisation for
Research and Treatment of Cancer (EORTC) (with the respective
protocol identifiers EORTC-19961 and ClinicalTrials.gov
NCT00003031). The protocol was approved by the appropriate
institutional review boards in all participating centers, and written
informed consent was obtained from all patients. The selection of
patients and conduct of the trial were as previously published [6].
Patients assessed by the attending physician as having no response
or intolerance to the initial randomized drug (VCZ or CAB) could
be switched to other licensed antifungal therapy (OLAT). Blood
specimens were obtained serially from trial patients at baseline,
upon recruitment, and at Weeks 1, 2 and 4 following commence-
ment of randomized anti-fungal therapy. The current study was a
post-hoc analysis of serial serum GM trends of patients receiving
anti-fungal treatment for IA. Serum GM was measured at a
central laboratory (Health Protection Agency Mycology Reference
Laboratory, Bristol, U.K.) within 2 years upon completion of the
trial and was performed according to the manufacturer’s
instructions (Platelia Aspergillus EIA, Bio-Rad Laboratories,
Marne-la-Coquette, France). Random testing for stability of the
stored samples showed an average GMI decrease of 11% over 13
months. Acute kidney injury (AKI) was defined as a 2-fold increase
in serum creatinine during anti-fungal therapy in relation to the
baseline level before starting treatment, or a level .3 mg/dL
(265 mmol/L) if the baseline value was.1.5 mg/dL (133 mmol/L)
[6].
Outcome measures were assessed by an independent and
blinded data review committee (DRC) based on reviews of clinical,
mycological and systematically-collected radiological data. As the
primary end-point, satisfactory clinical response was defined as a
complete or partial response at Week 12 after commencement of
anti-fungal therapy (W12 Response); poor response was defined as
treatment failure or stable disease (W12 Non-response), in
accordance with the pre-established assessment criteria of the
DRC. In cases whereby death had occurred prior to the stipulated
DRC assessment time-point or that the clinical data was
insufficient to determine an objective response, the DRC W12
Response was set as ‘indeterminate’. End-of-initial randomized
therapy (EORT) was a secondary endpoint reached when pre-
specified criteria to stop the randomized therapy and switch to
OLAT were attained. In patients who remained on their initial
randomized therapy until week 12, the EORT assessment and the
Week 12 assessment were the same. Post-hoc assessment of the
clinical response at EORT by the DRC (v.i.z. satisfactory,
unsatisfactory or indeterminate) used the same criteria as for the
W12 Response. The other definitive outcome measure was all-
cause survival at 12 weeks after the start of anti-fungal treatment.
In our analysis, only the GMI of patients who continued to
receive the primary randomized anti-fungal agent (CAB or VCZ)
at the specified intervals of therapy (v.i.z. Weeks 1, 2 and 4) were
considered. Patients who were switched from the primary trial
drug to OLAT were dropped from the analysis at the point of drug
switch. The time profile of GMI or DGMI (GMI-change between
2 specified time-points) for the different outcomes at week 12
(based on clinical response and survival at week 12) are presented
graphically by plotting the mean per time-point. The generalized
estimation equations (GEE) approach is used to test and estimate
changes in the effect size for GMI, accounting for repeated
measurements over time within patients. A Gaussian family
distribution is specified along with an identity link function and an
exchangeable correlation structure. Where relevant, sensitivity
analysis incorporating renal impairment as variable was per-
formed. All statistical evaluations were performed using STATA
release 12.0 (StataCorp, College Station, TX). The threshold for
statistical significance is set at p,0.05.
Results
Data from one hundred and forty-seven patients with proven
and probable IA [2] and who had GMI measurements performed
were studied, based on the modified intention-to-treat analysis [6].
Of these patients, 77 were randomized to receive CAB, while 70
received VCZ as primary therapy. The demographics of these
study patients are as described in Table 1. Treatment success at
W12 for patients who received CAB as primary therapy was
37.7% as compared to 55.7% for VCZ. Treatment success at the
EORT assessment for patients who were randomized to receive
CAB was 18.3% versus 54.3% for those randomized to VCZ
(p,0.001). Survival at end of study (at Week 12) was 66.2% for
patients initially randomized to CAB and 74.3% for patients
initially randomized to VCZ.
Serial GMI trends in relation to the specified outcomes
(satisfactory or unsatisfactory response) were studied categorically
between patients who received either VCZ or CAB as primary
therapy (Figures 1A–F). In these analyses, patients with an
‘indeterminate’ response, as assessed by the DRC, were excluded;
thus, only those with a DRC-determined non-response at either
Week 12 or EORT were assessed and compared with treated
patients who had responded to therapy (Figures 1A–D). We also
performed analyses that included the ‘indeterminate’ response
cases (but classed them as ‘non-response’) at either Week 12 or
EORT and obtained similar results (data not shown).
Patients who were randomized to VCZ and had a satisfactory
response at Wk12 showed a decreasing GMI at Week 1 and Week
2 relative to the GMI at baseline, as compared to those who
eventually failed treatment (p = 0.001 and p= 0.046 respectively,
Figure 1B). However, for patients randomized to receive CAB, this
early difference in GMI trend between W12 responders and non-
responders was delayed and not evident until Week 4 (Figure 1A).
At EORT, patients randomized to receive CAB (Figure 1C) and
assessed not to have responded to treatment showed persistently
elevated Baseline-to-Week 2 and Baseline-to-Week 4 GMI relative
to patients who responded to CAB (p= 0.022 and p= 0.046
respectively). In VCZ patients, there was no difference in GMI
Galactomannan Trends with Different Anti-Fungals
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trends between those who had a satisfactory or unsatisfactory
EORT response (Figure 1D).
For both antifungal drugs, initial GMI trends (between Baseline
and Week 2) were generally not prognostic for eventual survival in
this analysis. Notably, however, in patients randomized to CAB,
those who died before Week 12 showed a significantly greater
Baseline-to-Week 4 decrease in GMI as compared to the Week 12
survivors (Figure 1E).
Discussion
GMI quantification has been proposed as a surrogate for fungal
burden [1] and treatment response [4]. In this study we show that
temporal galactomannan trends are distinct in patients receiving
different antifungal treatment regimens. In IA patients who
received VCZ as primary therapy, a significant drop in GMI
from baseline to Week 1 was prognostic for a satisfactory clinical
response at Week 12, while persistence of an elevated GMI was
associated with eventual treatment failure (Figure 1B). However,
GMI trends suggesting failure on CAB treatment were seen later,
at Week 4 of therapy (Figure 1A). In summary, the distinction
between responders and non-responders was seen earlier in
patients on primary VCZ treatment than in those receiving
CAB. Progressive reduction of GMI however, was not a surrogate
for eventual survival.
Quantification of fungal burden in animal models treated with
either VCZ or CAB has shown that the former was more effective
in clearance of Aspergillus with reduced tissue colony counts [10],
from which galactomannan might be a surrogate for fungal load
[1]. Interestingly, in the VCZ primary treatment arm, the
promptness of response as reflected by clear GMI reduction
within the 1st 2 weeks of therapy was associated with a satisfactory
response at Week 12. Early persistence of elevated GMI, on the
other hand, may well indicate significant residual fungal burden as
a result of slow response to treatment (Figures 1A–B). In contrast,
in patients receiving CAB as primary therapy, prediction of
eventual the response using GMI as surrogate was only possible at
Week 4.
In CAB-treated patients, a persistently high (or unchanged)
GMI from baseline to Week 2 or Week 4 (Figure 1C) was linked to
the likelihood of switching earlier than VCZ to another antifungal
therapy at EORT. However, it is notable that only a minority (4
patients) had switched from CAB to OLAT on the grounds of poor
primary treatment response as assessed by the primary physician.
The major indication for the switch to OLAT was drug (especially
renal/electrolyte) intolerance [11]. CAB-associated intolerance is
thus a potential confounder that may herald an unsatisfactory IA
response to primary CAB treatment.
The capacity of amphotericin B to alter renal function is well
recognized and galactomannan levels are partly determined by
glomerular filtration rate, as it is also detectable in urine. As such,
the delayed changes in serial GMI observed in patients receiving
CAB, as compared to VCZ, might be influenced by differing rates
of renal clearance of circulating galactomannan. Indeed clinically,
the dissociation between GMI and IA treatment response in the
setting of renal failure has already been described [12]. However,
the extent to which amphotericin B and the development of acute
kidney injury affect the kinetics of renal clearance over time is not
well understood. To address this aspect in the patients who had
received CAB as primary therapy, we further incorporated AKI as
a variable in our analyses. The observed GMI trend differences
between responders and non-responders at EORT remained
largely unchanged (Baseline-to-Week 2 GMI change p= 0.022
became 0.026, and Baseline-to-Week 4 GMI change p= 0.046
became 0.064 respectively). The Baseline-to Week 4 GMI trend
difference between W12 survivors and non-survivors (p = 0.014)
became p= 0.05 with AKI as a co-variate. The above analyses
suggested that renal impairment in patients receiving CAB did not
influence GMI trend results to a significant extent.
Alternatively, these differences in GMI trends could be related
to the mode of action of both drugs. As a polyene, amphotericin B
acts principally through binding to ergosterol in the fungal plasma
membrane and creating transmembrane pores which induce cell
permeability and eventually death [13]. Voriconazole, a triazole,
inhibits ergosterol synthesis through P450 cytochrome-mediated
lanosterol demethylation [14]. Galactomannan, on the other
hand, is a polysaccharide moiety within the Aspergillus cell wall
lying exterior to the cell membrane [15]. So while both drugs exert
their effects at the level of the cell membrane, observations have
been made that azoles and polyenes can induce different changes
to the fungal cell wall structure and composition [16–18]. Thus,
they may also differentially influence the galactomannan content
and shedding.
The statistical difference in the GMI trend for survival in CAB-
treated subjects is unexpected. The GMI drop between Baseline
and Week 4 for CAB seems linked to the likelihood of mortality at
12 weeks. This was discordant in relation to the GMI trends at
Week 12 or at the EORT Response described above. This may be
a chance occurrence, as differences in the magnitude of change
Table 1. Demographics characteristics of study cohort of 147
patients.
Characteristics Patients (n =147) P value
CAB N=77 (%) VCZ N= 70 (%)
Sex
Male 51 (66.2) 48 (68.6) 0.861
Female 26 (33.8) 22 (31.4)
Certainty of Disease
Proven IA 8 (10.4) 9 (12.8) 0.797
Probable IA 69 (89.6) 61 (87.2)
Neutropenia 45 (58.4) 44 (62.9) 0.353
Underlying Disease
Leukaemia/Lymphoma 59 (76.6) 45 (64.3) 0.526
HSCT 14 (18.2) 19 (27.1)
Week 12 Response
Satisfactory 29 (37.7) 39 (55.7)
Unsatisfactory 15 (19.4) 10 (14.3) 0.09
Indeterminate 33 (42.9) 21 (30.0)
EORT Response
Satisfactory 14 (18.2) 38 (54.3)
Unsatisfactory 55 (71.4) 19 (27.1) 0.001
Indeterminate 8 (10.4) 13 (18.6)
Week 12 Survival
Alive 51 (66.2) 52 (74.3) 0.368
Dead 26 (33.8) 18 (25.7)
CAB: conventional amphotericin B deoxycholate. VCZ: voriconazole. IA: invasive
aspergillosis. HSCT: hematopoietic stem cell transplantation. EORT Response:
End-of-initial randomized therapy response. The comparison of demographic
and clinical characteristics between patients who received CAB or VCZ was
made using the chi-squared or ANOVA test as appropriate.
doi:10.1371/journal.pone.0090176.t001
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between the survivors and non-survivors, while statistically
significant, were small (Figure 1E). This is further mitigated by
an observation in similar IA patients (of which the study cohort
here is a subset) that mortality beyond 6 weeks of IA diagnosis and
treatment was more likely related to the status of underlying
primary disease than the effectiveness of anti-fungal treatment
[19]. Nonetheless, it remains to be well established whether
circulating galactomannan levels can be influenced by other
Figure 1. A–F Galactomannan index (GMI) trends of patients receiving as primary therapy, either conventional amphotericin B
(CAB, Panels A,C,E) or voriconazole (VCZ, Panels B,D,F) in relation to the respective outcomes. Geometric GMI (y-axis) means was
plotted over indicated time intervals. Only the GMI of patients who continued to receive the primary randomized anti-fungal agent (CAB or VCZ) at
the specified intervals of therapy were considered. Patients who were switched from the primary trial drug to OLAT were dropped from the analysis
at the point of drug switch. Table below each Panel indicates the number of patients still receiving the respective primary antifungal therapy (v.i.z.
CAB or VCZ) over time in each arm. The P value is indicative of the difference in the DGMIs between the two outcome-stratified arms from Baseline to
the indicated study interval (v.i.z. Weeks 1, 2 or 4) as enclosed by the horizontal bars.
doi:10.1371/journal.pone.0090176.g001
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important factors, such as the patient’s primary disease and
concurrent infections. Nonetheless concern that piperacillin-
tazobactam usage might have significantly confounded GMI level
is largely unfounded as this antibiotic saw its approval for use
towards the end of the clinical trial (for Protocol 130–307 outside
the US).
In conclusion, we demonstrate here that different anti-fungal
treatments yield distinct early GMI trends that may have
prognostic value. The increasing number of different classes of
anti-fungals currently in use against IA highlights the need to
further understand the variety of disease responses with different
drugs classes and the kinetics of biomarker monitoring. Our
findings illustrate this point and have potentially significant
implications for the management of IA.
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